A Phase 3 Clinical Trial With ISIS-TTRRx, a 2nd-Generation Antisense Oligonucleotide Targeting Transthyretin (TTR), for the Treatment of TTR Amyloid Cardiomyopathy

Orphanet Journal of Rare Diseases - United Kingdom
doi 10.1186/1750-1172-10-s1-p8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search